Q-Linea AB (publ) (OMX:QLINEA) announced today that its ASTar instrument and gram-negative panel have successfully completed an analytical evaluation by a prominent US reference laboratory. This significant milestone marks a pivotal moment for Q-Linea as it opens doors for the ASTar system to become an integral part of clinical routines in diagnosing and treating gram-negative bloodstream infections in the United States.

The ASTar system, renowned for its high capacity and fully automated 'load-and-go' functionality, is gaining traction among healthcare professionals. The ease of use and efficiency it offers make it an attractive option for hospitals aiming to optimize antibiotic treatment times and improve patient outcomes.

Currently, Q-Linea is engaged in discussions with the management of the reference laboratory to explore the integration of the ASTar system into clinical practices. Furthermore, additional evaluations are being conducted at several prestigious university hospitals across the United States, further expanding the system's footprint and credibility in the market.

Q-Linea's ASTar system is designed to significantly reduce the time taken to determine antibiotic susceptibility, a critical factor in treating conditions like sepsis and bloodstream infections. By ensuring that patients receive the correct treatment promptly, the ASTar system not only enhances patient care but also contributes to the sustainable use of antibiotics, preserving their efficacy for future generations.

Given the growing interest and the strategic discussions underway, Q-Linea is well-positioned to capitalize on the US market's demand for advanced diagnostic tools. Investors should consider holding their positions in Q-Linea, as the company's innovative solutions and expanding market presence indicate a promising future.